Grufity logoGrufity logo
StocksFundsSearch Filings

BioXcel Therapeutics Inc Stock Research

BTAI

18.70USD+0.76(+4.24%)Delayedas of 01 Jun 2023, 11:12 am

Market Summary

USD18.70+0.76
Delayedas of 01 Jun 2023, 11:12 am
4.24%

BTAI Alerts

BTAI Stock Price

BTAI RSI Chart

BTAI Valuation

Market Cap

522.1M

Price/Earnings (Trailing)

-2.79

Price/Sales (Trailing)

673.91

Price/Free Cashflow

-3.36

BTAI Price/Sales (Trailing)

BTAI Profitability

Return on Equity

-107.94%

Return on Assets

-55.99%

Free Cashflow Yield

-29.77%

BTAI Fundamentals

BTAI Revenue

Revenue (TTM)

774.7K

BTAI Earnings

Earnings (TTM)

-187.1M

Earnings Y/Y

-67.76%

Earnings Q/Q

3.67%

Price Action

52 Week Range

8.8034.13
(Low)(High)

Last 7 days

-30.8%

Last 30 days

-13.8%

Last 90 days

-40.1%

Trailing 12 Months

53.3%

BTAI Financial Health

Current Ratio

10.34

BTAI Investor Care

Shares Dilution (1Y)

4.00%

Diluted EPS (TTM)

-6.64

Peers (Alternatives to BioXcel Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
117.9B
26.2B
-7.64% -12.03%
14.89
4.5
-0.48% 38.34%
96.0B
27.0B
-5.50% 23.66%
17.2
3.55
-1.56% 23.65%
49.0B
15.1B
-4.27% -12.12%
10.25
3.26
-33.37% -67.32%
42.8B
10.1B
-4.73% 48.21%
13.67
4.24
-6.61% 115.98%
MID-CAP
8.7B
1.6B
-13.93% -4.24%
136.39
5.46
32.38% -10.36%
4.1B
-
17.13% 24.41%
-11.15
38.1
122.90% -29.67%
2.4B
76.7M
3.81% -9.32%
-7.51
30.96
41.73% -32.75%
2.2B
107.9M
-4.32% 100.88%
-4.54
20.39
54.84% 17.36%
SMALL-CAP
1.5B
119.0M
11.39% 8.39%
-5.38
12.62
-69.61% -584.39%
1.1B
10.0M
8.51% 30.70%
-6.18
107.56
215.65% -47.65%
694.6M
-
4.27% -85.45%
-0.6
0.35
72.89% 12.32%
495.9M
136.9M
-20.60% -78.14%
-2.11
3.62
116.83% -0.93%
186.8M
241.0M
-25.83% -69.32%
-1.47
0.78
113.96% 27.87%
165.4M
697.0K
50.34% -66.48%
-1.53
237.34
47.98% -35.48%
8.7M
-
-35.78% -88.38%
-0.11
3.21
0.51% -129.47%

Financials for BioXcel Therapeutics

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q12022Q42022Q3
Revenue106.6%775375548--
  S&GA Expenses15.9%79,69568,76161,963--
  R&D Expenses9.9%100,22791,23971,052--
Interest Expenses20.6%9,9068,213---
Net Income-12.9%-187,081-165,757-137,074--
Net Income Margin--250.14*----
Free Cahsflow--116,785----
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-12.5%180206245248211
  Current Assets-12.6%177203242245208
    Cash Equivalents-14.6%166194232233200
  Inventory-1.7%2.002.001.001.001.00
  Net PPE-7.4%1.001.001.001.001.00
Liabilities-1.5%12712911884.0017.00
  Current Liabilities-12.6%29.0033.0023.0020.0016.00
    LT Debt, Non Current2.2%95.0093.0092.0061.00-
Shareholder's Equity-31.0%53.0077.00127164194
  Retained Earnings-12.8%-464-411-356-314-277
  Additional Paid-In Capital5.9%517488484479471
Shares Outstanding3.4%29.0028.0028.0028.0028.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-14.7%-155-135-116-105-94.93
  Share Based Compensation6.1%18.0017.0015.0015.0018.00
Cashflow From Investing7.9%-0.14-0.15-0.17-0.25-
Cashflow From Financing-24.8%72.0096.0060.000.00-

Risks for BTAI

What is the probability of a big loss on BTAI?

100%


Probability that BioXcel Therapeutics stock will be more than 20% underwater in next one year

100%


Probability that BioXcel Therapeutics stock will be more than 30% underwater in next one year.

92.3%


Probability that BioXcel Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BTAI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BioXcel Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for BTAI

Cumulative Returns on BTAI

10.0%


5-Year Cumulative Returns

-27.2%


3-Year Cumulative Returns

What are the long-term rolling returns for BTAI?

FIve years rolling returns for BioXcel Therapeutics.

Annualized Returns

Which funds bought or sold BTAI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-18
JPMORGAN CHASE & CO
added
49.12
73,000
322,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-5.93
-46,000
203,000
-%
2023-05-17
Advisory Services Network, LLC
unchanged
-
-1,077
7,128
-%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
206
722,025
1,156,560
-%
2023-05-16
JANE STREET GROUP, LLC
new
-
199,886
199,886
-%
2023-05-16
Rockefeller Capital Management L.P.
sold off
-100
-19,000
-
-%
2023-05-15
Legal & General Group Plc
added
2.11
-23,485
184,398
-%
2023-05-15
Metropolitan Life Insurance Co/NY
reduced
-22.22
-9,091
18,940
-%
2023-05-15
NORTHERN TRUST CORP
reduced
-1.86
-683,095
3,949,670
-%
2023-05-15
UBS ASSET MANAGEMENT AMERICAS INC
sold off
-100
-294,405
-
-%

1–10 of 38

Latest Funds Activity

Are funds buying BTAI calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BTAI
No. of Funds

BioXcel Therapeutics News

GuruFocus.com
BioXcel Therapeutics to Partic.
GuruFocus.com,
4 hours ago
Stockhouse Publishing
InvestorsObserver
The Motley Fool
Yahoo Finance

Schedule 13G FIlings of BioXcel Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 04, 2023
bioxcel holdings, inc.
29.5%
8,546,750
SC 13G/A
Feb 14, 2023
bioxcel holdings, inc.
30.5%
8,546,750
SC 13G/A
Feb 14, 2023
alliancebernstein l.p.
0.1%
24,000
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
blackrock inc.
4.7%
1,312,403
SC 13G/A
Feb 03, 2023
blackrock inc.
5.2%
1,462,922
SC 13G
Feb 02, 2023
adage capital partners gp, l.l.c.
5.53%
1,548,591
SC 13G
Feb 14, 2022
alliancebernstein l.p.
5.4%
1,508,768
SC 13G
Feb 14, 2022
bioxcel holdings, inc.
30.5%
8,546,750
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A

BTAI Fair Value

Show Fair-Value

Recent SEC filings of BioXcel Therapeutics

View All Filings
Date Filed Form Type Document
May 24, 2023
4
Insider Trading
May 22, 2023
144
Notice of Insider Sale Intent
May 17, 2023
DEF 14A
DEF 14A
May 16, 2023
144/A
144/A
May 16, 2023
4
Insider Trading
May 16, 2023
4
Insider Trading
May 16, 2023
4
Insider Trading
May 15, 2023
144
Notice of Insider Sale Intent
May 15, 2023
144
Notice of Insider Sale Intent
May 09, 2023
10-Q
Quarterly Report

Latest Insider Trading transactions for BTAI

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-22
Mehta Vimal
sold
-167,641
25.7909
-6,500
ceo and president
2023-05-15
Rodriguez Javier
sold
-48,764
27.3192
-1,785
see remarks
2023-05-15
Steinhart Richard I
sold
-135,864
27.1727
-5,000
chief financial officer
2023-05-14
Steinhart Richard I
acquired
-
-
5,000
chief financial officer
2023-05-14
Rodriguez Javier
acquired
-
-
5,000
see remarks
2023-05-14
Mehta Vimal
acquired
-
-
15,000
ceo and president
2023-04-06
Nandabalan Krishnan
sold
-1,039,200
17.32
-60,000
-
2023-04-06
Nandabalan Krishnan
acquired
24,600
0.41
60,000
-
2023-03-21
Mehta Vimal
sold
-591,405
19.7135
-30,000
ceo and president
2023-03-21
Mehta Vimal
acquired
12,300
0.41
30,000
ceo and president

1–10 of 50

Vimal D. Mehta
90
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
Product revenue, net$ 206 
Operating expenses  
Cost of goods sold9 
Research and development27,800$ 18,559
Selling, general and administrative23,59512,921
Total operating expenses51,40431,480
Loss from operations(51,198)(31,480)
Other expense (income)  
Interest expense3,3677
Interest income(2,015)(15)
Other expense, net246 
Net loss$ (52,796)$ (31,472)
Basic net loss per share attributable to common stockholders (in dollars per share)$ (1.84)$ (1.12)
Diluted net loss per share attributable to common stockholders (in dollars per share)$ (1.84)$ (1.12)
Weighted average shares outstanding - basic28,616,00027,980,000
Weighted average shares outstanding - diluted28,61627,980

BTAI Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 165,521$ 193,725
Accounts receivable, net283248
Inventory1,9521,985
Prepaid expenses4,5063,067
Other current assets5,0063,843
Total current assets177,268202,868
Property and equipment, net1,0041,084
Operating lease right-of-use assets906976
Other assets925925
Total assets180,103205,853
Current liabilities  
Accounts payable7,74210,228
Accrued expenses17,06518,669
Due to related parties380422
Accrued interest3,0883,175
Other current liabilities484404
Total current liabilities28,75932,898
Long-term portion of operating lease liabilities703786
Derivative liabilities2,5742,343
Long-term debt95,06293,051
Total liabilities127,098129,078
Commitments and contingencies (Note 15)
Stockholders' equity  
Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of March 31, 2023 and December 31, 2022
Common stock, $0.001 par value, 100,000 shares authorized as of March 31, 2023 and December 31, 2022; 29,100 and 28,147 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively2928
Additional paid-in-capital517,317488,292
Accumulated deficit(464,341)(411,545)
Total stockholders' equity53,00576,775
Total liabilities and stockholders' equity$ 180,103$ 205,853